Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed supratentorial grade IV astrocytoma (glioblastoma multiforme)~* Underwent gross total resection within the past 6 weeks~  * Postoperative contrast-enhancing tumor extends ≤ 1 cm from the margin of the surgical cavity~ * 6-8 polifeprosan 20 with carmustine implants (Gliadel® wafers) were placed in the surgical resection cavity at time of surgery~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 1.5 mg/dL~* Transaminases ≤ 4 times upper limit of normal~Renal~* Creatinine ≤ 1.7 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known hypersensitivity reaction to temozolomide~* No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior immunotherapy for the brain tumor~* No prior biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide-receptor agonists, interferons, interleukins, tumor-infiltrating lymphocyte therapy, lymphokine-activated killer cell therapy, or gene therapy) for the brain tumor~Chemotherapy~* See Disease Characteristics~* No other prior chemotherapy for the brain tumor~Endocrine therapy~* No prior hormonal therapy for the brain tumor~* Prior glucocorticoid therapy allowed~Radiotherapy~* No prior radiotherapy for the brain tumor~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).